Pyralgina Plus 400 mg + 60 mg + 40 mg Tabletki powlekane بولندا - البولندية - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

pyralgina plus 400 mg + 60 mg + 40 mg tabletki powlekane

zakłady farmaceutyczne polpharma s.a. - metamizolum natricum monohydricum + coffeinum + drotaverini hydrochloridum - tabletki powlekane - 400 mg + 60 mg + 40 mg

Benlek 500 mg + 38,75 mg + 50 mg Tabletki بولندا - البولندية - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

benlek 500 mg + 38,75 mg + 50 mg tabletki

solinea sp. z o.o. sp.k. - metamizolum natricum monohydricum + thiamini hydrochloridum + coffeinum - tabletki - 500 mg + 38,75 mg + 50 mg

Vemonis Intense 400 mg + 60 mg + 40 mg Tabletki powlekane بولندا - البولندية - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

vemonis intense 400 mg + 60 mg + 40 mg tabletki powlekane

adamed pharma s.a. - metamizolum natricum + coffeinum + drotaverini hydrochloridum - tabletki powlekane - 400 mg + 60 mg + 40 mg

Tavneos الاتحاد الأوروبي - البولندية - EMA (European Medicines Agency)

tavneos

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - leki immunosupresyjne - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Nucala الاتحاد الأوروبي - البولندية - EMA (European Medicines Agency)

nucala

glaxosmithkline trading services - mepolizumab - astma - preparaty do obturacyjne choroby dróg oddechowych, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.